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Abstract
Sustained ventricular tachycardia (VT) is an important cause of morbidity and sudden death in 
patients with dilated cardiomyopathy. Although ICD effectively terminate VT episodes and 
improve survival, shocks reduce quality of life, and episodes of VT predict increased risk of 
heart failure and death despite effective therapy. Patients suffering recurrent VT episodes 
remain a challenge. Antiarrhytmic therapy reduces VT episodes, but it is associated with 
serious adverse events, and disappointing efficacy. Catheter ablation has emerged as an 
important option to control recurrent VT, but major procedure-related complications, and even 
death, are still issues to concern. And even with these armamentaria, some patients still have 
recurrent VT episodes and ICD shocks. We report on a patient with non-ischemic dilated 
cardiomyopathy and recurrent ventricular tachycardia resistant to multiple antiarrhytmic 
agents, in whom dronedarone was effective in completely suppressing ventricular tachycardia 
episodes.
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Background
Sustained ventricular tachycardia (VT) is an important cause of morbidity and sudden death in 
patients with dilated cardiomyopathy. Although ICDs effectively terminate VT episodes and 
improve survival, shocks reduce quality of life, and episodes of VT predict increased risk of 
heart failure and death despite effective therapy. Patients suffering recurrent VT episodes 
remain a challenge. Antiarrhythmic therapy reduces VT episodes, but it is associated with 
serious adverse events, and disappointing efficacy. Catheter ablation has emerged as an 
important option to control recurrent VT, but major procedure-related complications, and even 
death, are still issues of concern. And even with this armamentarium, some patients still have 
recurrent VT episodes and ICD shocks. We report on a patient with non-ischemic dilated 
cardiomyopathy and recurrent ventricular tachycardia resistant to multiple antiarrhythmic 
agents, in whom dronedarone was effective in completely suppressing ventricular tachycardia 
episodes.
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Case   Report                                                                  
An 81-year-old man with non-ischemic dilated cardiomyopathy and severe ventricular systolic 
dysfunction (EF 30%) underwent biventricular ICD implantation (St Jude Promote AccelTM), 
after suffering sudden cardiac death due to ventricular tachycardia. Baseline rhythm was atrial 
fibrillation   with   slow   ventricular   response.   He   was   on   amiodarone,   beta-blocker   and 
angiotensin receptor blocker at the time of implantation, without heart failure symptoms.      
The patient continued to have symptomatic VT episodes with appropriate ICD discharges. 
Amiodarone was increased, but it was discontinued due to severe hypothyroidism. He was 
placed on sotalol 80 mg twice a day, but soon stopped after patient developed QT 
prolongation and asthenia. Patient was switched to propafenone 300 mg 3 times daily, but 
again side effects (diarrhea, nausea-vomiting) led to therapy discontinuation. Symptomatic VT 
episodes with multiple morphologies requiring ICD discharges and/or emergency room visits 
continued, despite optimization of ATP therapy.                                                       
Procainamide   was   initiated   with   better   tolerance,   although   patient   continued   to   be 
symptomatic with frequent VT episodes. At this point in time, an echocardiogram showed 
marked left ventricular systolic function impairment (EF 15%). Of note, cardiac function in 
consecutive echocardiograms had initially remained stable after ICD implantation. The rest of 
pharmacological agents had not been modified. After myocardial ischemia was ruled out, a 
catheter ablation procedure was planned, but patient refused invasive procedures. Trying 
dronedarone was offered, with clear understanding of its off-label and compassionate use. 
After informed consent, patient was switched to droneradone 400 mg twice daily. On follow-
up, patient reported significant improvement of his symptoms, with just one episode of VT 
successfully treated with ATP therapy over the next 12 months, and systolic function recovery 
to prior 30% coinciding with the decrease of arrhythmic burden. Significant reduction of ICD 
shocks before and after droneradone initiation is shown in Figure 1.
Figure 1
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Discussion
Droneradone represents the latest generation of antiarrhythmic drugs, a multichannel blocking 
agent with molecular structure similar to amiodarone, but with a more favorable safety profile, 
as the drug is no iodinated and has less lipophilicity [1], The possibility to overcome 
extracardiac effects of long-term treatment with amiodarone in AF patients seemed particularly 
promising, as clinical studies had shown that dronedarone effectively reduces ventricular rate 
and may prevent or delay the recurrence of AF. Even more, the ATHENA trial showed 
significant reductions in a composite end point of all-cause mortality and cardiovascular 
hospitalization with dronedarone use, and a post hoc analysis of the ATHENA data also 
suggested a decrease in stroke risk with this agent [2,3]. This initial enthusiastic state drove to 
droneradone incorporation into American College of Cardiology Foundation (ACCF)/American 
Heart Association (AHA)/Heart Rhythm Society (HRS), and European Society of Cardiology 
(ESC) 2010 guidelines on AF, even as a drug of first-line treatment in the latter [4]. 
Unfortunately,   droneradone   is   clearly   less   effective   in   maintaining   sinus   rhythm   than 
amiodarone, and, although significantly safer, recently FDA and EMA recommended warnings 
about possible risk of severe liver injury.                                                                       
Dronedarone has not been specifically studied for patients with ventricular arrhythmias. 
However,   animal   studies   have   demonstrated   antiarrhytmic   properties   on   ventricular 
myocardium, and clinical experience may suggest it may be an alternative in selected cases 
[5,6]. In ATHENA trial patients on droneradone showed a reduction in arrhythmic death. 
Kowey et al reported a trend towards reduction in appropriate ICD shocks in patients on 
droneradone at high doses. Although this indication is not established, positive experience is 
accumulating in this setting. Fink et al reported suppression of VT episodes as read in device 
memory over 6 months follow-up in a patient with paroxysmal AF, ischemic cardiomyopathy 
and ICD implantation due to ventricular arrhythmias. Dronedarone was started as alternative to 
amiodarone because of intolerance [7]. Finally, Shaaraoui et al described recently suppression 
of recurrent ventricular tachycardia refractory to multiple drug therapy and catheter ablation in a 
DCM patient with mild ventricular dysfunction and no signs of heart failure [8].       
Use of droneradone in severely depressed ventricular function remains controversial, as its use 
in congestive heart failure patients may lead to worsening symptoms and even cardiogenic 
shock [9]. In the ANDROMEDA trial, dronedarone was associated with increased mortality 
when tested in New York Heart Association (NYHA) III/IV patients with left ventricular 
ejection fractions of less than 35%, who also had a recent hospitalization for decompensated 
heart   failure.                                                                      
In our case, droneradone suppressed dramatically the number of VT episodes, without 
impairing   heart   failure   symptoms,   and   even   restoring   ventricular   function   to   baseline, 
presumably due to the mid-term adverse consequences of frequent ventricular ectopy and runs 
of  non-sustained  and   sustained   VT.                                                                     
Although no definitive conclusions can be made with so few cases, the notion of a potential role 
for droneradone in controlling ventricular arrhythmias merits further exploration.           
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